Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.45 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.45 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | HEXA | P06865 | 3/20 | 0.39 |
| ▸ | HEXB | P07686 | 3/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15434725 | 0.85 | TLR8 (0.49) | TLR8TLR7NUDT1HEXAHEXB | |
| SCHEMBL31051087 | 0.85 | TLR8 (0.49) | TLR8TLR7NUDT1HEXAHEXB | |
| SCHEMBL9286486 | 0.85 | TLR8 (0.52) | TLR8TLR7NUDT1 | |
| SCHEMBL15434720 | 0.77 | TLR8 (0.39) | TLR8TLR7NUDT1HEXAHEXB | |
| SCHEMBL8515321 | 0.76 | NPSR1 (0.47) | TLR8TLR7 | |
| SCHEMBL15508427 | 0.76 | NPSR1 (0.46) | TLR8TLR7NUDT1HEXAHEXB | |
| SCHEMBL12705668 | 0.75 | HEXA (0.44) | TLR8TLR7HEXAHEXB | |
| SCHEMBL9287308 | 0.75 | TLR8 (0.55) | TLR8TLR7NUDT1MAPK1 | |
| SCHEMBL9607432 | 0.74 | TLR8 (0.41) | TLR8TLR7HEXAHEXBHSP90AA1 | |
| SCHEMBL15508426 | 0.74 | TLR8 (0.44) | TLR8TLR7NUDT1HEXAHEXB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018347-A1 | BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018347-A1 | BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE | MTOR, RICTOR, RPTOR | TLR8 4503/4885TLR7 3901/4885NUDT1 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.